[
    [
        {
            "time": "",
            "original_text": "医药生物行业周报:带量采购降价超预期,板块进入估值重构和结构分化期",
            "features": {
                "keywords": [
                    "医药生物",
                    "带量采购",
                    "降价",
                    "估值重构",
                    "结构分化"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报:带量采购降价超预期,板块进入估值重构和结构分化期",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]